Juvenile psoriatic arthritis research hub
5 indexed studies · 3 currently recruiting
- ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3 Multicenter, Open-label Study to Evaluate the Efficacy, Pharmacokinetics, Safety, and Immunogenicity of Subcutaneously Administered Ustekinumab or Guselkumab in Pediatric Participants With Active Juvenile Psoriatic Arthritis (PSUMMIT-Jr)
This study looks at two medicines, Stelara and Guselkumab, for young people with a type of arthritis called juvenile psoriatic arthritis. It checks how well they work, how safe they are, and how the body handles them.
France · Poland · Netherlands - recruitingPHASE3
An Open-label Study to Evaluate the Pharmacokinetics and Safety of Bimekizumab in Pediatric Study Participants With Active Juvenile Idiopathic Arthritis Subtypes Enthesitis-related Arthritis (Including Juvenile-onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis
This study is looking at a new medicine called Bimekizumab for children aged 2-18 with certain types of arthritis: enthesitis-related arthritis (including ankylosing spondylitis) and juvenile psoriatic arthritis. We want to see how the medicine works in the body.
Canada · France · Germany - active not recruitingPHASE3
A Study of Ixekizumab (LY2439821) in Children With Juvenile Idiopathic Arthritis Categories of Enthesitis-related Arthritis (Including Juvenile Onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis
This study is testing a new medicine called ixekizumab for children aged 2-17 with two types of juvenile arthritis: enthesitis-related arthritis (including a form of arthritis affecting the spine) and juvenile psoriatic arthritis. We want to see if it's safe and helps improve their condition, comparing it to another common medicine, adalimumab.
Argentina · Belgium · Czechia - recruitingPHASE3
A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab
This study looks at a new medicine called risankizumab for children aged 5-17 with a type of arthritis called juvenile psoriatic arthritis (jPsA). It aims to see how safe and effective it is compared to an existing medicine, adalimumab. Participants will receive injections.
United States · Australia · Canada - recruitingPHASE3
A Study to Evaluate the Drug Levels, Efficacy, and Safety of Deucravacitinib (BMS-986165) in Pediatric Participants With Juvenile Psoriatic Arthritis
This study is looking at a new medicine, Deucravacitinib, for children and teenagers aged 5 to 17 with a type of arthritis called Juvenile Psoriatic Arthritis. We want to see if it helps reduce their symptoms, how safe it is, and how much medicine is in their body.
United States · Brazil · Bulgaria